Why we invested in Peer AI’s agentic backbone for the next era of drug approvals

The life sciences are one of the most consequential industries for humanity, yet one of the slowest-moving. Every new therapy must navigate a mountain of regulatory documentation before reaching patients. We’re talking about 200,000+ pages spanning 1,500+ unique documents, each riddled with opportunities for errors, delays, or inconsistencies that can stall approvals for over a year. 

It’s no surprise that nearly one-third of FDA submissions have quality issues, with 75% of applications rejected due to incomplete or inaccurate data. For patients waiting on life-saving therapies, those lost months matter. For pharma and biotech companies, the cost of such delays can run into the billions.

That’s why SignalFire is proud to co-lead Peer AI’s $12.1 million fundraise alongside Flare Capital, with participation from Greycroft, Atria Ventures, Alumni Ventures, Gaingels, Mana Ventures, and top Health & PharmaTech angels. 

Peer AI is a leading agentic AI platform for life sciences regulatory documentation, enabling medical writing teams to draft high-quality submissions up to 94% faster, without compromising compliance.

Domain-specific agentic AI for regulatory medical writing

Peer AI is taking a highly specialized approach to addressing this significant market need: Life sciences-specific AI agents for medical writing that collaborate to complete complex, multi-stakeholder workflows for biopharma companies.

Peer has built a system that combines multiple specialized AI agents with an intuitive human-in-the-loop control layer to mirror how regulatory workflows actually operate:

• Data Source Agents: Extract information from complex, unstructured sources, including data tables, scans, and databases.
• Authoring Agents: Draft core regulatory documents (protocols, clinical study reports, INDs, investigator brochures, plain-language summaries, and more).
• Style and Validation Agents: Ensure formatting compliance and perform quality checks against FDA/EMA standards.

Human experts remain in the loop at critical control points, applying domain knowledge and oversight through Peer AI’s intuitive interface. This blend of AI acceleration plus expert validation is already showing remarkable results:

• Clinical Study Report (CSR) drafting time has been reduced from 40 days to 17 days
• Protocol turnaround has been cut down from 6 - 8 weeks to just 1 week
• Revision cycles are significantly shorter

By integrating seamlessly into existing life sciences medical writing workflows and tools, Peer AI has earned deep trust and enthusiasm from its biopharma customers.

Regulatory know-how meets AI-native product expertise

To build a successful solution for AI-driven regulatory documentation, you need a team that is perfectly bilingual: fluent in the nuances of life sciences workflows and the cutting edge of AI engineering.

At SignalFire, we seek founders who combine deep industry expertise with an AI-native product vision. Peer AI’s leadership team not only embodies both strengths but also brings the rare experience of scaling a company from founding to IPO:

• CEO and co-founder Anita Modi was a key leader at companies like Genos and athenahealth, bringing decades of experience in AI and life sciences, an extensive network of biopharma customers, and a track record of scaling Science37 to an IPO.
• Co-founder Chris Ceppi brings decades of experience as a founder and builder, primarily at companies in the cybersecurity sector, including Ping Identity. He was most recently the CTO at Science37, leading the product and engineering team through the company’s IPO.
• Co-founder Ravi Ramachandran brings decades of deep biopharma experience, having helped bring several drugs to market across companies such as Vertex Pharmaceuticals, Apellis, and PPD.
• The broader team comprises AI leaders from Google, expert medical writers who’ve been in the trenches of regulatory workflows, and former operators from companies like Benchling and Syneos, who know how to transform complex workflows into agile systems.

This all-star team is establishing the regulatory backbone for life sciences by transforming a historically fragmented, manual process into a unified agentic platform that keeps experts in control.

Real customers and real ROI in a $15B (and growing) category

Peer AI’s solution is a production-ready platform with clear ROI for some of the industry’s most sophisticated customers. We invested in Peer AI because it embodies the three secret ingredients for category-defining AI companies:

• Tackling a hair-on-fire problem: Regulatory documentation and submission is one of the largest bottlenecks between discovery and patient impact. A single-day delay in regulatory submission and approval represents $500,000 in lost sales, with an average delay of 435 days across the industry.
• Going deep, not broad: By building specialized agents for a specific industry vertical, Peer AI achieves accuracy and compliance levels that it believes horizontal AI solutions can’t replicate.
• Keeping humans in control: In heavily regulated domains, the winning AI products don’t replace experts; they hope to make them 10 times more effective.

The regulatory documentation market is currently valued at $15 billion and is projected to reach $19 billion by 2028, as submission volumes are expected to increase. Outsourcing manual processes can’t scale to meet that demand. AI has to be part of the solution.

Peer AI’s early traction shows how strong the pull is:

• 3X growth in daily active use among medical writers in 2025
• 6X increase in platform volume year-to-date
• Adopted by the top 20 pharma and biotech companies 

For founders building AI-native companies, Peer AI serves as a blueprint: identify the bottleneck that matters most, design for end-users rather than managers, and create a hybrid AI-plus-expert loop that compounds trust and adoption.

We are proud to back them as they build the foundational regulatory backbone for the next era of life sciences. Peer AI is backed by leading advisors, including Ariel Katz, CEO and co-founder of H1, a data, analytics, and AI platform connecting the world to the right doctors; Brian Longo, veteran life sciences advisor and former executive at Veeva Systems; and Hanlin Tang, co-founder of MosaicML and CTO for Neural Networks at Databricks.

We’re excited to support Anita and the Peer AI team as they redefine the regulatory infrastructure for the life sciences, ultimately helping patients access life-changing therapies faster. 

The Peer AI agentic platform is available today. Learn more about Peer AI and meet their team at upcoming events, including RAPS Convergence, AMWA Medical Writing & Communications Conference, SyncUP Summit, and CNS Summit, to learn more and get a demo.

At SignalFire, we’re not just writing checks; we’re building alongside the founders that we back. Our Beacon AI engine helps identify design partners and market opportunities, our in-house recruiting team has placed thousands of operators into high-growth startups, and our network of advisors includes world-class AI researchers, Health & PharmaTech veterans, and GTM experts.

If you’re a founder building in Health & PharmaTech to reshape the $140B biopharma outsourcing playbook like Peer AI, we’d love to connect. Apply here to join an industry leaders’ lunch we’re hosting at HLTH, or email me at sooah@signalfire.com.